Public Law 94-380
94th Congress

An Act

To amend the Public Health Service Act to authorize the establishment and implementation of an emergency national swine flu immunization program and to provide an exclusive remedy for personal injury or death arising out of the manufacture, distribution, or administration of the swine flu vaccine under such program.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, That this Act may be cited as the "National Swine Flu Immunization Program of 1976".

SEC. 2. Section 317 of the Public Health Service Act (42 U.S.C. 247b) is amended by inserting after subsection (i) the following new subsections:

"(j) (1) The Secretary is authorized to establish, conduct, and support (by grant or contract) needed activities to carry out a national swine flu immunization program until August 1, 1977 (hereinafter in this section referred to as the ‘swine flu program’). The swine flu program shall be limited to the following:

"(A) The development of a safe and effective swine flu vaccine.

"(B) The preparation and procurement of such vaccine in sufficient quantities for the immunization of the population of the States.

"(C) The making of grants to State health authorities to assist in meeting their costs in conducting or supporting, or both, programs to administer such vaccine to their populations, and the furnishing to State health authorities of sufficient quantities of such swine flu vaccine for such programs.

"(D) The furnishing to Federal health authorities of appropriate quantities of such vaccine.

"(E) The conduct and support of training of personnel for immunization activities described in subparagraphs (C) and (D) of this paragraph and the conduct and support of research on the nature, cause, and effect of the influenza against which the swine flu vaccine is designed to immunize, the nature and effect of such vaccine, immunization against and treatment of such influenza, and the cost and effectiveness of immunization programs against such influenza.

"(F) The development, in consultation with the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, and implementation of a written informed consent form and procedures for assuring that the risks and benefits from the swine flu vaccine are fully explained to each individual to whom such vaccine is to be administered. Such consultation shall be completed within two weeks after enactment of this Act, or by September 1, 1976, whichever is sooner. Such procedures shall include the information necessary to advice individuals with respect to their rights and remedies arising out of the administration of such vaccine.

"(G) Such other activities as are necessary to implement the swine flu program.
(2) The Secretary shall submit quarterly reports to the Congress on the administration of the swine flu program. Each such report shall provide information on—

(A) the current supply of the swine flu vaccine to be used in the program;

(B) the number of persons inoculated with such vaccine since the last report was made under this paragraph and the immune status of the population;

(C) the amount of funds expended for the swine flu program by the United States, each State, and any other entity participating in the program and the costs of each such participant which are associated with the program, during the period with respect to which the report is made; and

(D) the epidemiology of influenza in the United States during such period.

(3) Any contract for procurement by the United States of swine flu vaccine from a manufacturer of such vaccine shall (notwithstanding any other provision of law) be subject to renegotiation to eliminate any profit realized from such procurement (except that with respect to vaccine against the strain of influenza virus known as influenza A/Victoria/75 profit shall be allowed but limited to an amount not exceeding a reasonable profit), as determined pursuant to criteria prescribed by the Secretary, and the contract shall expressly so provide. Such criteria shall specify that any insurance premium amount which is included in the price of such procurement contract and which is refunded to the manufacturer under any retrospective, experience-rating plan or similar rating plan shall in turn be refunded to the United States.

(4) No funds are authorized to be appropriated to carry out the activities of the swine flu program authorized in subparagraphs (A), (B), (D), (E), and (F) of paragraph (1) of this subsection in addition to the funds appropriated by Public Law 94–266.

(k)(l)(A) The Congress finds that—

(i) in order to achieve the participation in the program of the agencies, organizations, and individuals who will manufacture, distribute, and administer the swine flu vaccine purchased and used in the swine flu program and to assure the availability of such vaccine in interstate commerce, it is necessary to protect such agencies, organizations, and individuals against liability for other than their own negligence to persons alleging personal injury or death arising out of the administration of such vaccine;

(ii) to provide such protection and to establish an orderly procedure for the prompt and equitable handling of claims by persons alleging such injury or death, it is necessary that an exclusive remedy for such claimants be provided against the United States because of its unique role in the initiation, planning, and administration of the swine flu program; and

(iii) in order to be prepared to meet the potential emergency of a swine flu epidemic, it is necessary that a procedure be instituted for the handling of claims by persons alleging such injury or death until Congress develops a permanent approach for handling claims arising under programs of the Public Health Service Act.
“(B) To—

“(i) assure an orderly procedure for the prompt and equitable handling of any claim for personal injury or death arising out of the administration of such vaccine; and

“(ii) achieve the participation in the swine flu program of—

(I) the manufacturers and distributors of the swine flu vaccine,

(II) public and private agencies or organizations that provide inoculations without charge for such vaccine or its administration and in compliance with the informed consent form and procedures requirements prescribed pursuant to subparagraph (F) of paragraph (1) of this subsection, and

(III) medical and other health personnel who provide or assist in providing inoculations without charge for such vaccine or its administration and in compliance with such informed consent form and procedures requirements,

it is the purpose of this subsection to establish a procedure under which all such claims will be asserted directly against the United States under section 1346(b) of title 28, United States Code, and chapter 171 of such title (relating to tort claims procedure) except as otherwise specifically provided in this subsection.

“(2) (A) The United States shall be liable with respect to claims submitted after September 30, 1976 for personal injury or death arising out of the administration of swine flu vaccine under the swine flu program and based upon the act or omission of a program participant in the same manner and to the same extent as the United States would be liable in any other action brought against it under such section 1346(b) and chapter 171, except that—

“(i) the liability of the United States arising out of the act or omission of a program participant may be based on any theory of liability that would govern an action against such program participant under the law of the place where the act or omission occurred, including negligence, strict liability in tort, and breach of warranty;

“(ii) the exceptions specified in section 2680(a) of title 28, United States Code, shall not apply in an action based upon the act or omission of a program participant; and

“(iii) notwithstanding section 2401(b) of title 28, United States Code, if a civil action or proceeding for personal injury or death arising out of the administration of swine flu vaccine under the swine flu program is brought within two years of the date of the administration of such vaccine and is dismissed because the plaintiff in such action or proceeding did not file an administrative claim with respect to such injury or death as required by such chapter 171, the plaintiff in such action or proceeding shall have 30 days from the date of such dismissal or two years from the date the claim arose, whichever is later, in which to file such administrative claim.

“(B) For purposes of this subsection, the term ‘program participant’ as to any particular claim means the manufacturer or distributor of the swine flu vaccine used in an inoculation under the swine flu program, the public or private agency or organization that provided an inoculation under the swine flu program without charge for such vaccine or its administration and in compliance with the
informed consent form and procedures requirements prescribed pursuant to subparagraph (F) of paragraph (1) of this subsection, and the medical and other health personnel who provided or assisted in providing an inoculation under the swine flu program without charge for such vaccine or its administration and in compliance with such informed consent form and procedures requirements.

“(3) The remedy against the United States prescribed by paragraph (2) of this subsection for personal injury or death arising out of the administration of the swine flu vaccine under the swine flu program shall be exclusive of any other civil action or proceeding for such personal injury or death against any employee of the Government (as defined in section 2671 of title 28, United States Code) or program participant whose act or omission gave rise to the claim.

“(4) The Attorney General shall defend any civil action or proceeding brought in any court against any employee of the Government (as defined in such section 2671) or program participant (or any liability insurer thereof) based upon a claim alleging personal injury or death arising out of the administration of vaccine under the swine flu program. Any such person against whom such civil action or proceeding is brought shall deliver all process served upon him (or an attested true copy thereof) to whoever is designated by the Secretary to receive such papers, and such person shall promptly furnish copies of the pleadings and process therein to the United States attorney for the district embracing the place wherein the civil action or proceeding is brought, to the Attorney General, and to the Secretary.

“(5) (A) Upon certification by the Attorney General that a civil action or proceeding brought in any court against any employee of the Government (as defined in such section 2671) or program participant is based upon a claim alleging personal injury or death arising out of the administration of vaccine under the swine flu program, such action or proceeding shall be deemed an action against the United States under the provisions of title 28, United States Code, and all references thereto. If such action or proceeding is brought in a district court of the United States, then upon such certification the United States shall be substituted as the party defendant.

“(B) Upon a certification by the Attorney General under subparagraph (A) of this paragraph with respect to a civil action or proceeding commenced in a State court, such action or proceeding shall be removed, without bond at any time before trial, by the Attorney General to the district court of the United States of the district and division embracing the place wherein it is pending and be deemed an action brought against the United States under the provisions of title 28, United States Code, and all references thereto; and the United States shall be substituted as the party defendant. The certification of the Attorney General with respect to program participant status shall conclusively establish such status for purposes of such initial removal. Should a district court of the United States determine on a hearing on a motion to remand held before a trial on the merits that an action or proceeding is not one to which this subsection applies, the case shall be remanded to the State court.

“(C) Where an action or proceeding under this subsection is precluded because of the availability of a remedy through proceedings for compensation or other benefits from the United States as provided
by any other law, the action or proceeding shall be dismissed, but in
that event the running of any limitation of time for commencing, or
filing an application or claim in, such proceedings for compensation
or other benefits shall be deemed to have been suspended during the
pendency of the civil action or proceeding under this subsection.
“(6) A program participant shall cooperate with the United States
in the processing or defense of a claim or suit under such section
1346(b) and chapter 171 based upon alleged acts or omissions of the
program participant. Upon the motion of the United States or any
other party, the status as a program participant shall be revoked by
the district court of the United States upon finding that the program
participant has failed to so cooperate, and the court shall substitute
such former participant as the party defendant in place of the United
States and, upon motion, remand any such suit to the court in which
it was instituted.
“(7) Should payment be made by the United States to any claimant
bringing a claim under this subsection, either by way of administrative
settlement or court judgment, the United States shall have, notwith­
standing any provision of State law, the right to recover for that
portion of the damages so awarded or paid, as well as any costs of
litigation, resulting from the failure of any program participant
to carry out any obligation or responsibility assumed by it under a
contract with the United States in connection with the program or
from any negligent conduct on the part of any program participant
in carrying out any obligation or responsibility in connection with
the swine flu program. The United States may maintain such action
against such program participant in the district court of the United
States in which such program participant resides or has its principal
place of business.
“(8) Within one year of the date of the enactment of the National
Swine Flu Immunization Program of 1976, and semiannually there­
after, the Secretary shall submit to the Congress a report on the con­
duct of settlement and litigation activities under this subsection,
specifying the number, value, nature, and status of all claims made
thereunder, including the status of claims for recovery made under
paragraph (7) of this subsection and a detailed statement of the
reasons for not seeking such recovery.
“(l) For the purposes of subsections (j) and (k) of this section—
“(1) the phrase ‘arising out of the administration’ with refer­
ce to a claim for personal injury or death under the swine flu
program includes a claim with respect to the manufacture or
distribution of such vaccine in connection with the provision of
an inoculation using such vaccine under the swine flu program;
“(2) the term ‘State’ includes the District of Columbia, Puerto
Rico, the Virgin Islands, Guam, American Samoa, and the Trust
Territory of the Pacific Islands; and
“(3) the term ‘swine flu vaccine’ means the vaccine against
the strain of influenza virus known as influenza A/New Jersey/76
(Hsw 1N1), or a combination of such vaccine and the vaccine
against the strain of influenza virus known as influenza
A/Victoria/75.”.
Sec. 3. The Secretary of Health, Education, and Welfare shall conduct, or provide for the conduct of, a study of the scope and extent of liability for personal injuries or death arising out of immunization programs and of alternative approaches to providing protection against such liability (including a compensation system) for such injuries. Within one year of the date of the enactment of this Act, the Secretary shall report to the Congress the findings of such study and such recommendations for legislation (including proposed drafts to carry out such recommendations) as the Secretary deems appropriate.

Approved August 12, 1976.